GoodRx (GDRX) FDA Approvals

GoodRx's Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by GoodRx (GDRX). Over the past two years, GoodRx has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Zepbound. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Zepbound FDA Regulatory Events

Zepbound is a drug developed by GoodRx for the following indication: for chronic weight management in adults with obesity. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Provided Update - March 6,2026

• Drug: Zepbound
• Announced Date: March 6, 2026
• Indication: for chronic weight management in adults with obesity

GoodRx announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct.

GoodRx announced a collaboration with Eli Lilly to offer employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (single-patient-use) through GoodRx Employer Direct. The program lets self-insured employers subsidize Lilly’s discounted $449 medication price so employees face lower out-of-pocket costs for Zepbound KwikPen.

Employer contributions are applied directly to the medication cost, and GoodRx combines the manufacturer’s discounted pricing with employer funding in real time at checkout. The service also offers optional telemedicine to help with prescribing and fulfillment, aiming to simplify how employees obtain and pay for the medicine.

GoodRx describes the model as a scalable, transparent way for employers to manage rising demand for GLP-1 obesity treatments while helping employees afford therapy. The partnership is positioned to expand access to Zepbound while giving employers a predictable way to support medication costs.